Clearstead Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.1M Buy
14,067
+591
+4% +$82.9K 0.02% 379
2026
Q2
$1.7M Sell
13,476
-3,306
-20% -$436K 0.02% 415
2026
Q1
$2.34M Buy
16,782
+13,228
+372% +$1.85M 0.02% 331
2025
Q4
$436K Sell
3,554
-68
-2% -$8.26K 0.01% 699
2025
Q3
$402K Sell
3,622
-1,539
-30% -$175K 0.01% 696
2025
Q2
$572K Buy
5,161
+2,175
+73% +$231K 0.01% 577
2025
Q1
$335K Buy
2,986
+292
+11% +$30.1K 0.01% 678
2024
Q4
$249K Sell
2,694
-428
-14% -$38.5K ﹤0.01% 787
2024
Q3
$262K Sell
3,122
-85
-3% -$6.49K ﹤0.01% 767
2024
Q2
$220K Buy
3,207
+5
+0.2% +$334 ﹤0.01% 794
2024
Q1
$216K Sell
3,202
-57
-2% -$4.38K 0.01% 453
2023
Q4
$264K Sell
3,259
-20
-0.6% -$1.56K 0.01% 422
2023
Q3
$246K Buy
3,279
+501
+18% +$38.5K 0.02% 400
2023
Q2
$214K Sell
2,778
-101
-4% -$8.06K 0.01% 421
2023
Q1
$239K Buy
2,879
+476
+20% +$39.4K 0.02% 369
2022
Q4
$206K Sell
2,403
-374
-13% -$29.6K 0.02% 376
2022
Q3
$171K Buy
2,777
+487
+21% +$30.7K 0.02% 384
2022
Q2
$142K Buy
2,290
+135
+6% +$8.36K 0.01% 431
2022
Q1
$128K Buy
2,155
+1,085
+101% +$69.4K 0.01% 499
2021
Q4
$78K Sell
1,070
-5,576
-84% -$384K 0.01% 580
2021
Q3
$464K Buy
6,646
+196
+3% +$13.8K 0.03% 249
2021
Q2
$444K Buy
6,450
+131
+2% +$8.75K 0.03% 242
2021
Q1
$408K Sell
6,319
-406
-6% -$26.2K 0.03% 241
2020
Q4
$392K Buy
6,725
+526
+8% +$31.7K 0.04% 228
2020
Q3
$392K Sell
6,199
-312
-5% -$21.6K 0.04% 210
2020
Q2
$501K Buy
6,511
+5,631
+640% +$432K 0.06% 174
2020
Q1
$66K Buy
+880
New +$60.8K 0.01% 371
2017
Q3
– Sell
-3,455
Closed -$245K – 251
2017
Q2
$245K Sell
3,455
-965
-22% -$64.2K 0.04% 208
2017
Q1
$300K Buy
4,420
+833
+23% +$58.6K 0.04% 178
2016
Q4
$257K Buy
+3,587
New +$267K 0.04% 181

Other funds holding GILD

Clearstead Advisors's GILD Position: Q3 2026 in Review

Clearstead Advisors increased its Gilead Sciences (GILD) stake by 4.4% in Q3 2026, buying an estimated $82.9K and bringing the position to 14,067 shares worth $2.1M. The position accounts for 0.02% of the portfolio, ranked #379.

Clearstead Advisors first reported a position in GILD in Q4 2016 and has held it in 30 quarters since. The position peaked at $2.34M in Q1 2026. 2,341 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Clearstead Advisors held 14,067 shares of Gilead Sciences worth $2.1M as of Q3 2026.
  • Clearstead Advisors bought 591 Gilead Sciences shares in Q3 2026, an estimated $82.9K.
  • Gilead Sciences made up 0.02% of Clearstead Advisors's portfolio in Q3 2026, its #379 holding.
  • Clearstead Advisors first reported a position in Gilead Sciences in Q4 2016 and has held it in 30 quarters since.
  • Clearstead Advisors's Gilead Sciences position peaked at $2.34M in Q1 2026.
  • 2,341 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.